{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-000154","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2026-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.905347+00:00","generated_at":"2026-05-16T11:08:26.944029+00:00","sec_items":["7.01"],"event_type":"other","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioCryst increases ORLADEYO WAC by ~9% to $48,488 per 28-day pack","bullets":["Effective January 9, 2026, WAC for ORLADEYO (berotralstat) raised from $44,484.33 to $48,487.92 per 28-day pack.","The price increase applies to both the 150mg and 110mg capsule strengths.","BioCryst's sole marketed product ORLADEYO is approved for hereditary angioedema prophylaxis."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-000154","json":"https://secwatch.observer/filing/0001171843-26-000154.json","markdown":"https://secwatch.observer/filing/0001171843-26-000154.md","text":"https://secwatch.observer/filing/0001171843-26-000154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184326000154/0001171843-26-000154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184326000154/f8k_010826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:08:26.944029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}